BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) saw strong trading volume on Friday . 3,089,034 shares traded hands during mid-day trading, an increase of 227% from the previous session's volume of 945,257 shares.The stock last traded at $94.56 and had previously closed at $104.31.
Wall Street Analysts Forecast Growth
A number of research firms have commented on BNTX. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an "overweight" rating in a report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and issued a $136.00 price target on shares of BioNTech in a research note on Monday, September 8th. Truist Financial reaffirmed a "buy" rating and issued a $155.00 price objective (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a report on Monday, June 2nd. Twelve analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $134.97.
View Our Latest Stock Report on BioNTech
BioNTech Stock Performance
The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm has a 50 day moving average of $108.30 and a two-hundred day moving average of $103.74. The stock has a market cap of $23.60 billion, a PE ratio of -61.34 and a beta of 1.39.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same period last year, the company earned ($3.36) earnings per share. The firm's revenue for the quarter was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its holdings in BioNTech by 27.3% in the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company's stock valued at $208,000 after purchasing an additional 418 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in BioNTech by 5.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 8,619 shares of the company's stock valued at $919,000 after acquiring an additional 414 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after purchasing an additional 305 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its stake in shares of BioNTech by 2.8% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 667,635 shares of the company's stock worth $71,083,000 after purchasing an additional 18,351 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of BioNTech by 6.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company's stock valued at $135,800,000 after purchasing an additional 80,005 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Recommended Stories
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
